Viridian Therapeutics, Inc.\DE Income Statement (2013-2026) | VRDN

1Y3Y5Y7Y10YAll
Download Data
Income Statement Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
8.61M11.18M11.92M
Revenue & cost
Revenue (Quarter)
1.09M0.21M0.21M0.22M0.26M1.20M0.10M0.10M0.07M0.07M0.07M0.07M0.07M0.09M0.07M0.07M0.07M70.57M0.13M0.14M
Gross Profit (Quarter)
Operating items
Research & Development (Quarter)
12.56M8.12M22.39M17.75M21.71M22.12M5.60M50.74M40.08M30.39M38.56M40.94M56.19M69.16M71.96M76.83M86.63M86.26M10.00M77.63M
Selling, General & Administrative (Quarter)
6.52M6.22M6.90M8.36M8.11M8.86M9.85M21.83M19.26M20.91M32.99M15.03M16.07M14.41M15.58M17.10M20.22M24.32M33.67M38.68M
Other Operating Expenses (Quarter)
33.72M-0.20M-0.26M-0.04M0.45M-2.12M-0.67M
Operating Expenses (Quarter)
19.09M14.34M29.30M26.11M29.82M30.98M49.17M72.57M59.35M51.30M71.55M55.97M72.26M83.57M87.54M93.94M106.84M110.58M122.88M116.31M
Operating Income (Quarter)
-18.00M-14.13M-29.08M-25.89M-29.56M-29.79M-49.07M-72.47M-59.27M-51.22M-71.48M-55.90M-72.19M-83.48M-87.47M-93.87M-106.77M-40.01M-122.75M-116.17M
EBIT (Quarter)
-18.00M-14.13M-29.08M-25.89M-29.56M-29.79M-49.07M-72.47M-59.27M-51.22M-71.48M-55.90M-72.19M-83.48M-87.47M-93.87M-106.77M-40.01M-122.75M-116.17M
Non-operating items
Interest & Investment Income (Quarter)
0.03M0.09M0.14M0.20M0.23M1.04M3.45M4.49M4.38M4.16M-12.30M-0.70M-0.18M7.51M8.52M0.26M-0.18M5.52M27.03M7.87M
Other Non Operating Income (Quarter)
7.53M
Non Operating Income (Quarter)
0.03M0.09M0.14M0.20M0.07M0.88M3.28M4.32M4.21M3.56M4.62M7.36M7.19M6.79M7.75M6.95M6.03M5.41M2.39M11.27M
Net income details
EBT (Quarter)
-17.96M-14.04M-29.14M-25.69M-29.54M-28.94M-45.59M-68.19M-55.06M-47.66M-84.18M-57.69M-72.96M-91.49M-79.09M-94.16M-111.67M-35.05M-99.00M-111.76M
Profit After Tax (Quarter)
-17.96M0.01M50.31M-25.69M-29.49M0.14M-129.09M-68.15M-55.06M-47.55M-66.86M-48.54M-64.99M-76.69M-80.32M-86.66M-100.73M-34.60M222.33M-105.91M
Income from Continuing Operations (Quarter)
-17.96M-14.04M-29.14M-25.69M-29.54M-28.94M-45.59M-68.19M-55.06M-47.66M-84.18M-57.69M-72.96M-91.49M-79.09M-94.16M-111.67M-35.05M-99.00M-111.76M
Consolidated Net Income (Quarter)
-17.96M-14.04M-29.14M-25.69M-29.54M-28.94M-45.59M-68.19M-55.06M-47.66M-84.18M-57.69M-72.96M-91.49M-79.09M-94.16M-111.67M-35.05M-99.00M-111.76M
Income towards Parent Company (Quarter)
-17.96M-14.04M-29.14M-25.69M-29.54M-28.94M-45.59M-68.19M-55.06M-47.66M-84.18M-57.69M-72.96M-91.49M-79.09M-94.16M-111.67M-35.05M-99.00M-111.76M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-17.96M-14.04M-28.95M-25.69M-29.54M-28.94M-45.59M-68.19M-55.06M-47.66M-84.18M-57.69M-72.96M-91.49M-79.09M-94.16M-111.67M-35.05M-99.00M-111.76M
Additional items
EPS (Basic) (Quarter)
-2.22-1.26-2.43-0.98-1.06-0.86-1.42-1.61-1.27-1.09-1.88-0.94-1.14-1.38-2.59-2.77-3.31-1.02-3.32-3.42
EPS (Diluted) (Quarter)
-2.22-1.26-2.43-0.98-1.06-0.86-1.42-1.61-1.27-1.09-1.88-0.94-1.14-1.38-1.19-1.16-1.37-0.43-1.22-1.37
Shares Outstanding (Quarter)
8.11M11.18M11.92M26.13M27.76M33.74M32.09M42.24M43.25M43.65M44.76M61.10M63.85M66.42M30.58M33.95M33.71M34.29M29.86M32.71M
Shares Outstanding (Diluted) (Quarter)
8.11M11.18M11.92M26.13M27.76M33.74M32.09M42.24M43.25M43.65M44.76M61.10M63.85M66.42M66.42M81.34M81.34M81.34M81.34M81.34M
EBITDA (Quarter)
-18.00M-14.13M-29.08M-25.89M-29.56M-29.79M-49.07M-72.47M-59.27M-51.22M-71.48M-55.90M-72.19M-83.48M-87.47M-93.87M-106.77M-40.01M-122.75M-116.17M
Interest Expenses (Quarter)
0.20M0.20M0.20M-0.03M0.20M0.17M0.60M0.40M1.09M0.60M15.52M0.14M0.55M4.72M0.56M3.28M3.46M